Repare Therapeutics ( (RPTX) ) has provided an announcement.
On March 31, 2025, Repare Therapeutics announced significant leadership changes, with Lloyd Segal resigning as President and CEO, effective April 11, 2025, to pursue other opportunities. Steve Forte, the current CFO, will assume the roles of President and CEO, while Sandra Alves is promoted to Chief Accounting Officer. These changes come as Repare focuses on advancing its Phase 1 clinical trials and exploring strategic partnerships, aiming to enhance its position in the precision oncology market.
More about Repare Therapeutics
Repare Therapeutics is a clinical-stage precision oncology company that utilizes its proprietary synthetic lethality approach to discover and develop novel cancer therapies. The company focuses on genomic instability and DNA damage repair, with a clinical-stage pipeline that includes RP-1664, RP-3467, and lunresertib.
YTD Price Performance: -20.45%
Average Trading Volume: 277,361
Technical Sentiment Signal: Buy
Current Market Cap: $44.64M
For a thorough assessment of RPTX stock, go to TipRanks’ Stock Analysis page.